(Q33846405)

English

A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

Juergen M Schanzer

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Katharina Wartha

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Rebecca Croasdale

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Samuel Moser

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Klaus-Peter Künkele

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Carola Ries

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Werner Scheuer

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Harald Duerr

8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sandra Pompiati

9

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Jan Pollman

10

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Jan Stracke

11

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Wilma Lau

12

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Stefan Ries

13

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Ulrich Brinkmann

14

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Christian Klein

15

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Pablo Umana

16

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

19 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Journal of Biological Chemistry

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

289

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

18693-18706

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Blinatumomab: a historical perspective

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Role of MetMAb (OA-5D5) in c-MET active lung malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

EGFR-targeted therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Oligomeric forms of single chain immunoglobulin (scIgG).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Insulin and insulin-like growth factor signalling in neoplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Single chain Fab (scFab) fragment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Anti-epidermal growth factor receptor drugs in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Complement recruitment using bispecific diabodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

The epidermal growth factor receptor as a target for therapy in breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Presence of somatomedin receptors on primary human breast and colon carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081915

5 July 2018

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M113.528109

21 January 2018

Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M113.528109

21 January 2018

High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M113.528109

21 January 2018

GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M113.528109

21 January 2018

A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M113.528109

21 January 2018

Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M113.528109

21 January 2018

Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M113.528109

21 January 2018

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M113.528109

21 January 2018

'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the insulin-like growth factor receptor type 1

1 reference

https://pubmed.ncbi.nlm.nih.gov/24841203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1074/JBC.M113.528109

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33846405&oldid=1960294414"